ICOS and neoplasm: Anti-PD-1 and anti-CTLA-4 treatments both induce the expansion of specific subsets of tumor-infiltrating exhausted-like T cells, and anti-CTLA-4 additionally engages ICOS+ Th1-like CD4 T cells [80].